Abstract
Among critically ill COVID-19 patients, bacterial coinfections may occur, and timely appropriate therapy may be limited with culture-based microbiology due to turnaround time and diagnostic yield challenges (e.g. antibiotic pre-exposure). We performed a systematic review and meta-analysis of the impact of BioFire® FilmArray® Pneumonia Panel in detecting bacteria and clinical management among critically ill COVID-19 patients admitted to the ICU. Seven studies with 558 patients were included. Antibiotic use before respiratory sampling occurred in 28-79% of cases. The panel incidence of detections was 33% (95% CI 0.25 to 0.41, I 2 =32%) while culture yielded 18% (95% CI 0.02 to 0.45; I 2 =93%). The panel was associated with approximately a 1 and 2 day decrease in turnaround for identification and common resistance targets, respectively. The panel may be an important tool for clinicians to improve antimicrobial use in critically ill COVID-19 patients.
Keywords: Bacterial; BioFire Pneumonia Panel; COVID-19; Pneumonia; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Pneumonia, Bacterial, BioFire Pneumonia Panel, 【초록키워드】 Meta-analysis, SARS-CoV-2, therapy, Pneumonia, diagnostic, systematic review, ICU, Critically ill, Culture, Patient, Clinical management, Bacteria, targets, incidence, respiratory, antibiotic use, COVID-19 patients, Bacterial, antibiotic, COVID-19 patient, Bacterial coinfection, critically ill COVID-19 patients, 95% CI, clinician, bacterial coinfections, decrease, IMPROVE, performed, occurred, occur, Panel, 【제목키워드】 Meta-analysis, Pneumonia, Patient, identification, Ill,